Finch Therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. We use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients lives.